TITLE

Intraabdominal desmoid tumour presenting with perforation

AUTHOR(S)
Jalini, L; Hemming, D.; Bhattacharya, V.
PUB. DATE
April 2006
SOURCE
Surgeon (Edinburgh University Press);Apr2006, Vol. 4 Issue 2, p114
SOURCE TYPE
Academic Journal
DOC. TYPE
Case Study
ABSTRACT
We present a rare case of a desmoid tumour presenting with perforation of the small bowel, Although desmoid is classified pathologically as a benign tumour, its infiltrative nature leads to a locally aggressive mass, which can invade surrounding structures and organs making surgical resection difficult. Some unresectable tumours show oestrogen receptor positive cells and can be managed with tamoxifen. The aetiology, investigation and management options are briefly described
ACCESSION #
21994865

 

Related Articles

  • Tamoxifen Update. Sugerman, Deborah Tolmach // JAMA: Journal of the American Medical Association;8/28/2013, Vol. 310 Issue 8, p866 

    The article provides information on the drug Tamoxifen. Tamoxifen is a drug that blocks the effects of the hormone estrogen. It is used as a treatment for breast cancer patients whose tumors have estrogen receptors, called ER positive. It is often used after surgery or radiation therapy and also...

  • Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer. Larsen, Sarah L.; Yde, Christina W.; Laenkholm, Anne-Vibeke; Rasmussen, Birgitte B.; Duun-Henriksen, Anne Katrine; Bak, Martin; Lykkesfeldt, Anne E.; Kirkegaard, Tove // BMC Cancer;2015, Vol. 15 Issue 1, p1 

    Background: Resistance to antiestrogen therapy is a major clinical challenge in the treatment of estrogen receptor α (ER)-positive breast cancer. The aim of the study was to explore the growth promoting pathways of antiestrogen resistant breast cancer cells to identify biomarkers and novel...

  • MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Atanaskova, Natasha; Keshamouni, Venkateshwar G.; Krueger, Jospeh S.; Schwartz, Janice A. // Oncogene;6/6/2002, Vol. 21 Issue 25, p4000 

    Provides information on a study which examined the effect of the cross-talk on estradiol-mediated signaling, tumor growth and its effect on anti-estrogen therapy. Members of the nuclear receptor family of ligand-activated transcription factors; Capability of hormone-induced activation of...

  • The future of the new selective estrogen receptor modulators. Palacios, Santiago // Menopause International;Mar2007, Vol. 13 Issue 1, p27 

    Selective estrogen receptor modulators (SERMs) are compounds that display mixed estrogen agonist/antagonist activity. Currently, four SERMs are licensed for clinical use: tamoxifen, toremifene, clomifene and raloxifene. The STAR and RUTH trials have provided useful data about the potential role...

  • HE4 expression is associated with hormonal elements and mediated by importin-dependent nuclear translocation. Lokich, Elizabeth; Singh, Rakesh K.; Han, Alex; Romano, Nicole; Naohiro Yano; Kyukwang Kim; Moore, Richard G. // Scientific Reports;7/4/2014, p1 

    Antiestrogens including tamoxifen and fulvestrant have been evaluated as chemotherapeutics for ovarian cancer, particularly in cases of platinum resistant disease. Human epididymis protein 4 (HE4) is highly overexpressed in women with ovarian cancer and overexpression of HE4 has been found to...

  • Popular breast cancer drug could backfire in rare cases.  // New Scientist;7/7/2007, Vol. 194 Issue 2611, p18 

    The article discusses a study that found the drug Tamoxifen, which is frequently given to women suffering from breast cancer, to cause cancer proliferation by behaving like the hormone oestrogen. Studies have already shown that oestrogen can protect cancer cells from the immune system. The...

  • Selective Estrogen Receptor Modulators.  // Encyclopedic Reference of Molecular Pharmacology;2004, p844 

    A definition of the term "selective estrogen receptor modulators" is presented. It refers to synthetic compounds with partially agonistic and partially antagonistic estrogenic properties. They inhibit bone resorption through the mechanisms known for estrogens. Selective estrogen receptor...

  • Autocrine human growth hormone expression leads to resistance of MCF-7 cells to tamoxifen. Mojarrad, Majid; Momeny, Majid; Mansuri, Fatemeh; Abdolazimi, Yassan; Tabrizi, Mina Hajifaraj; Ghaffari, Seyed Hamidollah; Tavangar, Seyed Mohammad; Modarressi, Mohammad Hussein // Medical Oncology;Jun2010, Vol. 27 Issue 2, p474 

    Tamoxifen is the most common antiestrogen used in the treatment of estrogen-positive breast cancer but its adverse effects and also resistance to this drug are serious challenges in the treatment of breast cancer. Characterization of mechanisms responsible for these adverse effects can lead to...

  • Estradiol and Tamoxifen Induce Cell Migration through GPR30 and Activation of Focal Adhesion Kinase (FAK) in Endometrial Cancers with Low or without Nuclear Estrogen Receptor α (ERα). Tsai, Chia-Lung; Wu, Hsien-Ming; Lin, Chiao-Yun; Lin, Yi-Jun; Chao, Angel; Wang, Tzu-Hao; Hsueh, Swei; Lai, Chyong-Huey; Wang, Hsin-Shih // PLoS ONE;Sep2013, Vol. 8 Issue 9, p1 

    Estrogens and tamoxifen (an antiestrogen) exert their actions by activation of estrogen receptor (ER) through genomic and non-genomic mechanisms and are implicated in the development of endometrial cancer. Previous reports have demonstrated that estradiol and tamoxifen induce proliferation of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics